NL301049I1 - Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Info

Publication number: NL301049I1
Authority: NL; Netherlands
Prior art keywords: crisaborale; optionally; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2005-02-16

Application number

NL301049C

Other languages

English (en)

Other versions

NL301049I2 (nl

Original Assignee

Anacor Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-16

Filing date

2020-06-24

Publication date

2020-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301049(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-06-24 Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc

2020-07-01 Publication of NL301049I1 publication Critical patent/NL301049I1/nl

2020-09-10 Publication of NL301049I2 publication Critical patent/NL301049I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL301049C 2005-02-16 2020-06-24 crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301049I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65406005P	2005-02-16	2005-02-16
EP06735282.3A EP1853251B1 (en)	2005-02-16	2006-02-16	Halogen-substituted boronophthalides for the treatment of infections

Publications (2)

Publication Number	Publication Date
NL301049I1 true NL301049I1 (nl)	2020-07-01
NL301049I2 NL301049I2 (nl)	2020-09-10

Family

ID=36917059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301049C NL301049I2 (nl)	2005-02-16	2020-06-24	crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (26)

Country	Link
US (11)	US7582621B2 (nl)
EP (4)	EP1853251B1 (nl)
JP (6)	JP5038912B2 (nl)
KR (4)	KR101337045B1 (nl)
CN (2)	CN101160124A (nl)
AU (3)	AU2006214247C1 (nl)
BR (1)	BRPI0608431B8 (nl)
CA (1)	CA2597982C (nl)
CY (3)	CY1120695T1 (nl)
DK (3)	DK3424932T3 (nl)
ES (4)	ES2872962T3 (nl)
FR (1)	FR20C1024I2 (nl)
HK (3)	HK1109735A1 (nl)
HU (4)	HUE040060T2 (nl)
IL (2)	IL185080A (nl)
LT (1)	LTC2343304I2 (nl)
LU (1)	LUC00157I2 (nl)
MX (1)	MX369262B (nl)
NL (1)	NL301049I2 (nl)
NZ (3)	NZ560448A (nl)
PL (4)	PL1853251T3 (nl)
PT (4)	PT3424932T (nl)
RU (3)	RU2414906C2 (nl)
SI (3)	SI2987796T1 (nl)
WO (1)	WO2006089067A2 (nl)
ZA (4)	ZA200707408B (nl)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7820186B2 (en) *	2001-12-21	2010-10-26	Galderma Research & Development	Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
EP1853251B1 (en) *	2005-02-16	2013-04-24	Anacor Pharmaceuticals, Inc.	Halogen-substituted boronophthalides for the treatment of infections
US7793666B2 (en) *	2005-07-28	2010-09-14	Innovation Biomedical Devices, Inc.	Apparatus and method for treatment of infected nail
RU2008131324A (ru)	2005-12-30	2010-02-10	Анакор Фармасьютикалз, Инк. (Us)	Борсодержащие малые молекулы
SI2719388T1 (sl) *	2006-02-16	2019-06-28	Anacor Pharmaceuticals, Inc.	Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem
EP2015757A4 (en) *	2006-05-02	2011-01-26	Anacor Pharmaceuticals Inc	HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
EP1900378A1 (en) *	2006-08-31	2008-03-19	Novartis AG	Pharmaceutical compositions for the treatment of fungal infections
JO3598B1 (ar)	2006-10-10	2020-07-05	Infinity Discovery Inc	الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910321B1 (fr)	2006-12-21	2009-07-10	Galderma Res & Dev S N C Snc	Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) *	2006-12-21	2009-02-13	Galderma Res & Dev S N C Snc	Emulsion comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) *	2007-06-20	2019-10-20	Anacor Pharmaceuticals Inc	جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en)	2008-01-03	2009-07-09	Gareth Winckle	Compositions and methods for treating diseases of the nail
JP2015178508A (ja) *	2008-01-09	2015-10-08	アナコールファーマシューティカルズ，インコーポレイテッド	抗炎症剤としてのホウ素含有小分子
EP2187893A4 (en) *	2008-03-06	2012-02-22	Anacor Pharmaceuticals Inc	SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
US8039450B2 (en)	2008-03-06	2011-10-18	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-inflammatory agents
CN102046179B (zh) *	2008-04-09	2015-01-14	英菲尼提制药公司	脂肪酸酰胺水解酶抑制剂
US20100256092A1 (en) *	2008-05-12	2010-10-07	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
WO2010011354A2 (en) *	2008-07-25	2010-01-28	Innovation Biomedical Devices, Inc.	Enchanced trans-keratin drug delivery
WO2010027975A1 (en)	2008-09-04	2010-03-11	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
US8461336B2 (en)	2008-09-04	2013-06-11	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
WO2010045503A1 (en)	2008-10-15	2010-04-22	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-protozoal agents
SG172040A1 (en) *	2008-12-17	2011-07-28	Anacor Pharmaceuticals Inc	Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
CA2757679A1 (en)	2009-04-07	2010-10-14	Infinity Pharmaceuticals, Inc.	Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en)	2009-04-07	2010-10-14	Infinity Pharmaceuticals, Inc.	Inhibitors of fatty acid amide hydrolase
EP2458995A1 (en)	2009-07-28	2012-06-06	Anacor Pharmaceuticals, Inc.	Trisubstituted boron-containing molecules
WO2011019616A1 (en)	2009-08-14	2011-02-17	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as antiprotozoal agents
WO2011019618A1 (en)	2009-08-14	2011-02-17	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as antiprotozoal agents
WO2011019612A1 (en)	2009-08-14	2011-02-17	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as antiprotozoal agents
MX2012002031A (es)	2009-08-19	2012-07-04	Anacor Pharmaceuticals Inc	Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
US20110124597A1 (en) *	2009-09-25	2011-05-26	Anacor Pharmaceuticals, Inc.	Boron containing small molecules
US8979820B2 (en)	2009-10-09	2015-03-17	Cynthia S. Bailey	Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en)	2009-10-20	2011-04-28	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) *	2009-11-11	2013-06-11	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
WO2011063293A1 (en)	2009-11-20	2011-05-26	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as antihelminth agents
WO2011094450A1 (en)	2010-01-27	2011-08-04	Anacor Pharmaceuticals, Inc	Boron-containing small molecules
JP2013518886A (ja)	2010-02-03	2013-05-23	インフイニトイプハルマセウトイカルスインコーポレイテッド	脂肪酸アミドヒドロラーゼ阻害剤
WO2011116348A1 (en)	2010-03-19	2011-09-22	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-protozoal agent
US8039494B1 (en)	2010-07-08	2011-10-18	Dow Pharmaceutical Sciences, Inc.	Compositions and methods for treating diseases of the nail
PT3412676T (pt)	2010-08-10	2020-05-19	Rempex Pharmaceuticals Inc	Derivados cíclicos de éster de ácido borónico, método para a sua preparação e suas utilizações terapêuticas
KR102152901B1 (ko)	2010-09-07	2020-09-07	아나코르 파마슈티칼스 인코포레이티드	세균 감염을 치료하기 위한 벤족사보롤 유도체
US9012491B2 (en)	2011-08-31	2015-04-21	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9162999B2 (en)	2011-09-28	2015-10-20	Wisconsin Alumni Research Foundation	Catalytic conversion of cellulose to fuels and chemicals using boronic acids
AU2012320382B2 (en) *	2011-10-07	2015-11-26	Syngenta Participations Ag	Method for protecting useful plants or plant propagation material
AR088669A1 (es)	2011-11-21	2014-06-25	Lilly Co Eli	Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) *	2011-11-21	2014-06-25	Lilly Co Eli	Moleculas pequeñas que contienen boro
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (en)	2012-07-06	2014-01-09	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
EA201591004A1 (ru)	2013-01-04	2016-02-29	Ремпекс Фармасьютикалз, Инк.	Производные бороновой кислоты и их терапевтическое применение
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko)	2013-01-04	2015-09-09	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US8669207B1 (en)	2013-01-30	2014-03-11	Dow Agrosciences, Llc.	Compounds and compositions
US10070649B2 (en)	2013-01-30	2018-09-11	Agrofresh Inc.	Volatile applications against pathogens
US11039617B2 (en)	2013-01-30	2021-06-22	Agrofresh Inc.	Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US9585396B2 (en)	2013-01-30	2017-03-07	Agrofresh Inc.	Volatile applications against pathogens
EP2950644B1 (en)	2013-01-30	2017-07-19	AgroFresh Inc.	Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts
US9446131B2 (en)	2013-01-31	2016-09-20	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US8778365B1 (en)	2013-01-31	2014-07-15	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9433680B2 (en)	2013-01-31	2016-09-06	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9452173B2 (en)	2013-01-31	2016-09-27	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9598443B2 (en)	2013-02-01	2017-03-21	Anacor Pharmaceuticals, Inc.	Boron containing small molecules as antiprotozoal agents
AR094961A1 (es)	2013-03-15	2015-09-09	Lilly Co Eli	1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) *	2013-06-05	2014-09-11	Agrofresh Inc.	Compounds and compositions
CN104224810B (zh) *	2013-06-20	2017-04-19	中国科学院上海生命科学研究院	一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko)	2013-07-30	2016-07-05	동아에스티 주식회사	트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
PT3030519T (pt)	2013-08-09	2022-01-27	Anacor Pharmaceuticals Inc	Compostos de benzoxaborol tricíclicos e utilizações dos mesmos
JP6516759B2 (ja)	2013-10-03	2019-05-22	ダウファーマシューティカルサイエンシーズ，インコーポレイティド	安定化エフィナコナゾール組成物
CA2931144C (en)	2013-11-22	2020-02-04	Dow Pharmaceutical Sciences, Inc.	Anti-infective methods, compositions, and devices
EP3107921A1 (en) *	2014-02-17	2016-12-28	Syngenta Participations AG	Microbiocidally active benzoxaboroles
US10065029B2 (en)	2014-03-03	2018-09-04	Cook Medical Technologies Llc	Mechanical dilator
LT3140310T (lt)	2014-05-05	2019-11-25	Rempex Pharmaceuticals Inc	Boronato druskų sintezė ir jų panaudojimas
ES2985626T3 (es)	2014-05-05	2024-11-06	Melinta Therapeutics Inc	Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
JP2015212249A (ja) *	2014-05-05	2015-11-26	アナコールファーマシューティカルズ，インコーポレイテッド	化合物および爪光沢剤
KR20170007347A (ko) *	2014-05-12	2017-01-18	애그로프레쉬 인크.	병원체에 대항하는 휘발성 적용
CA2947041A1 (en)	2014-05-19	2015-11-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP3164406B1 (en)	2014-07-01	2024-12-25	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
TW201625649A (zh)	2014-07-01	2016-07-16	第一三共股份有限公司	作爲抗菌劑的三環化合物
ES2890461T3 (es)	2014-10-21	2022-01-19	Hexima Ltd	Un método de tratamiento de infecciones fúngicas
US10662205B2 (en)	2014-11-18	2020-05-26	Qpex Biopharma, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41495A (fr)	2015-02-12	2017-12-19	Anacor Pharmaceuticals Inc	Composés benzoxaborole et leurs utilisations
WO2016149393A1 (en)	2015-03-17	2016-09-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
KR101580077B1 (ko) *	2015-03-28	2015-12-24	한국콜마주식회사	시크로피록스 함유 네일락카 조성물
EP3280262B1 (en) *	2015-04-09	2022-07-06	The Penn State Research Foundation	Synergistic benzoxaborole-containing anti-fungicidal composition
CA2979891A1 (en)	2015-04-09	2016-10-13	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as antiprotozoal agents
WO2016201440A1 (en) *	2015-06-12	2016-12-15	The Regents Of The University Of California	Spiroindolinones and therapeutic uses thereof
CA3014757C (en) *	2015-08-06	2020-01-14	The Penn State Research Foundation	Benzoxaborole-containing coating resistant to cellulose-supportable fungus
CN106467557B (zh) *	2015-08-18	2019-05-03	北京海美桐医药科技有限公司	他瓦硼罗的一种制备方法
AU2016362668C1 (en)	2015-11-30	2020-11-05	Anacor Pharmaceuticals, Llc	Topical pharmaceutical formulations for treating inflammatory-related conditions
EP3971191A1 (en)	2016-03-02	2022-03-23	Bill And Melinda Gates Foundation	Boron-containing small molecules
EP3423159A4 (en) *	2016-03-02	2019-11-06	Anacor Pharmaceuticals, Inc.	BORN SMALL MOLECULES
US10874679B2 (en)	2016-03-02	2020-12-29	Bill & Melinda Gates Foundation	Boron-containing small molecules
TW201735792A (zh)	2016-03-07	2017-10-16	農業保鮮股份有限公司	使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
AU2017229096A1 (en)	2016-03-07	2018-09-06	Agrofresh Inc.	Vaporized administration of pesticides
US11447506B2 (en)	2016-05-09	2022-09-20	Anacor Pharmaceuticals, Inc.	Crystal forms of crisaborole in free form and preparation method and use thereof
EP3456722A4 (en) *	2016-05-09	2019-12-18	Anacor Pharmaceuticals, Inc	CRISABOROL CRYSTAL SHAPES IN FREE FORM AND PRODUCTION METHOD AND USE THEREOF
MY196909A (en)	2016-06-30	2023-05-09	Qpex Biopharma Inc	Boronic acid derivatives and therapeutic uses thereof
EP3484895A1 (en)	2016-07-12	2019-05-22	Pliva Hrvatska D.O.O.	Solid state forms of crisaborole
US10743232B1 (en)	2016-11-15	2020-08-11	Sprint Spectrum L.P.	Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (en) *	2016-12-22	2018-06-28	Laboratorios Lesvi, Sl	Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) *	2017-01-31	2017-03-15	Drug Delivery Solutions Ltd	Topical composition
WO2018150327A1 (en) *	2017-02-14	2018-08-23	Wavelength Enterprises Ltd	Crisaborole production process
WO2018164959A1 (en) *	2017-03-09	2018-09-13	The Penn State Research Foundation	Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
US10981939B2 (en)	2017-05-12	2021-04-20	Biophore India Pharmaceuticals Pvt. Ltd.	Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole)
US10865217B2 (en)	2017-05-23	2020-12-15	Msn Laboratories Private Limited, R & D Center	Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
EP3694864B1 (en)	2017-10-11	2025-03-05	Qpex Biopharma, Inc.	Boronic acid derivatives and synthesis thereof
EP4119566A1 (en)	2017-11-02	2023-01-18	Halcyon Labs Private Limited	Novel process for the preparation tavaborole and its intermediates
CA3120976A1 (en) *	2017-11-30	2019-06-06	Boragen, Inc.	Benzoxaborole compounds and formulations thereof
US10329311B1 (en)	2017-12-21	2019-06-25	Olon S.P.A.	Process for the preparation of crisaborole
CN108148085B (zh)	2018-01-04	2019-11-01	合肥医工医药股份有限公司	具有抑制磷酸二酯酶4的化合物、制法及其药物用途
BR112020013794B1 (pt)	2018-01-09	2023-05-02	Halcyon Labs Private Limited	Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal
US10597410B2 (en)	2018-02-02	2020-03-24	Dipharma Francis S.R.L.	Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) *	2018-04-03	2018-08-28	苏州尚宜佳生物科技有限公司	一种克立硼罗温敏凝胶剂及其制备方法和应用
CA3097127A1 (en)	2018-04-20	2019-10-24	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
GB201809378D0 (en) *	2018-06-07	2018-07-25	Glaxosmithkline Ip Dev Ltd	Novel compounds
CN108659024A (zh) *	2018-07-24	2018-10-16	武汉轻工大学	克立硼罗的制备方法
EP3829538A1 (en) *	2018-07-31	2021-06-09	MC2 Therapeutics Limited	Topical composition
AU2019325436B2 (en)	2018-08-18	2023-10-26	5Metis, Inc.	Solid forms of substituted benzoxaborole and compositions thereof
CR20210163A (es) *	2018-10-05	2021-06-24	Pfizer	Inhibidores de pde4 que contienen boro
US20220160649A1 (en)	2019-03-20	2022-05-26	Rita DOBMEYER	Pharmaceutical composition
WO2021015841A1 (en) *	2019-07-25	2021-01-28	Massachusetts Institute Of Technology	Boron-containing pharmacophore
CN110664756B (zh) *	2019-10-09	2020-11-17	吉林大学	一种小儿外伤喷雾剂及其制备方法
US20230340530A1 (en)	2020-08-31	2023-10-26	Pfizer Inc.	Methods of Protecting RNA
CN114644645B (zh) *	2022-03-08	2023-05-26	南京农业大学	3-吲哚取代苯硼唑类化合物及其制备方法和应用
EP4384185A1 (en) *	2022-06-23	2024-06-19	Micurx Pharmaceuticals, Inc.	Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
GB202306663D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Combination therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2260336A (en)	1939-10-16	1941-10-28	Dow Chemical Co	Method of preparation of organic borates
US3686398A (en)	1970-07-20	1972-08-22	Chevron Res	10,9-boroxarophenanthrene as fungicides
GB1396904A (en) *	1972-08-11	1975-06-11	Ici Ltd	Method for the control of micro-organisms
US4766113A (en)	1975-10-24	1988-08-23	Chapman Chemical Company	Antimicrobial compositions and methods of using same
US4602011A (en)	1975-10-24	1986-07-22	Chapman Chemical Company	Antimicrobial compositions and methods of using same
US4716035A (en)	1985-05-24	1987-12-29	The Procter & Gamble Company	Oral compositions and methods for treating gingivitis
US5962498A (en)	1986-06-11	1999-10-05	Procyon Pharmaceuticals, Inc.	Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en)	1987-01-30	1990-01-16	Colgate-Palmolive Company	Antibacterial antiplaque oral composition
US4919934A (en)	1989-03-02	1990-04-24	Richardson-Vicks Inc.	Cosmetic sticks
US5514696A (en) *	1992-05-06	1996-05-07	Bristol-Myers Squibb Co.	Phenyl sulfonamide endothelin antagonists
SG47101A1 (en)	1992-07-31	1998-03-20	Us Bioscience	Crystalline amifostine compositions and methods for the preparation and use of same
US5348947A (en)	1993-05-07	1994-09-20	American Cyanamid Company	Diarylboron ester and thioester fungicidal agents
US5348948A (en)	1993-05-07	1994-09-20	American Cyanamid Company	2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5594151A (en)	1994-01-28	1997-01-14	Prolinx, Inc.	Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) *	1994-06-09	1994-08-03	Zeneca Ltd	Compound, composition and use
US5688258A (en)	1995-05-02	1997-11-18	The Procter & Gamble Company	Disposable cover for an absorbent materials
US6083903A (en) *	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) *	1995-01-17	1995-03-08	Zeneca Ltd	Composition and use
JPH09124620A (ja) *	1995-10-11	1997-05-13	Bristol Myers Squibb Co	置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en)	1995-11-22	2004-07-20	Medtronic Minimed, Inc.	Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
GB9604926D0 (en)	1996-03-08	1996-05-08	Sandoz Ltd	Organic compounds
EP2223920A3 (en)	1996-06-19	2011-09-28	Aventis Pharma Limited	Substituted azabicyclic compounds
US5831046A (en)	1996-08-05	1998-11-03	Prolinx, Incorporated	Boronic acid-contaning nucleic acid monomers
WO1998012206A1 (en)	1996-09-19	1998-03-26	The Board Of Trustees Of Leland Stanford Jr. University	Dna adenine methyltransferases and uses thereof
DE69730737D1 (de)	1996-12-02	2004-10-21	Chisso Corp	Optisch aktive nitroalkohol-derivate, optisch aktive aminoalkohol-derivate und verfahren zu ihrer herstellung
US6221640B1 (en)	1997-05-14	2001-04-24	Cubist Pharmaceuticals, Inc.	Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en)	1997-12-12	2000-10-31	Rutgers, The State University Of New Jersey	Heterocyclic cytotoxic agents
DE19829947A1 (de)	1998-07-04	2000-01-05	Bayer Ag	Elektrolumineszierende Anordnungen mit Bor-Chelaten
TR200102277T2 (tr)	1998-11-06	2002-01-21	Basf Aktiengesellschaft Ag.	Üç halkalı (Trisiklik) pirazol türevleri
US6462036B1 (en)	1998-11-06	2002-10-08	Basf Aktiengesellschaft	Tricyclic pyrazole derivatives
EP1155698A4 (en)	1999-01-29	2003-01-15	Nitto Kasei Co Ltd	ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
CN1370170A (zh)	1999-05-25	2002-09-18	宾夕法尼亚州研究基金会	Dna甲基转移酶抑制剂
US6306628B1 (en)	1999-08-25	2001-10-23	Ambergen, Incorporated	Methods for the detection, analysis and isolation of Nascent proteins
EP1767629B1 (en)	1999-08-25	2011-04-20	Ambergen, Inc.	Methods for the detection, analysis and isolation of nascent proteins
US6921763B2 (en) *	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
WO2001025226A1 (en)	1999-10-05	2001-04-12	Bethesda Pharmaceuticals, Inc.	Dithiolane derivatives
JP2003519187A (ja)	2000-01-06	2003-06-17	マランテックホールディングリミテッドライアビリティカンパニー	癌管理のための電子活性化合物の使用方法
US6521619B2 (en)	2000-06-29	2003-02-18	Icos Corporation	Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
EP1303625A2 (en)	2000-07-14	2003-04-23	Zycos Inc.	Alpha-msh related compounds and methods of use
CA2428191A1 (en)	2000-11-07	2002-05-30	Bristol-Myers Squibb Company	Acid derivatives useful as serine protease inhibitors
JP2004524281A (ja)	2000-11-30	2004-08-12	ザペンステートリサーチファウンデイション	Ｄｎａメチルトランスフェラーゼ阻害剤
DE10110051C2 (de)	2001-03-02	2003-07-03	Clariant Gmbh	Verfahren zur Herstellung von Boron- und Borinsäuren
ES2332090T3 (es)	2001-04-06	2010-01-26	Biocryst Pharmaceuticals, Inc.	Compuestos biarilicos como inhibidores de serina proteasa.
GB0117645D0 (en)	2001-07-19	2001-09-12	Isis Innovation	Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de)	2001-09-07	2003-03-27	Clariant Gmbh	Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
JPWO2003033002A1 (ja)	2001-10-11	2005-02-03	御子柴　克彦	細胞内カルシウム濃度上昇抑制剤
EP1463739A2 (en)	2002-01-10	2004-10-06	The Pennsylvania State Research Foundation	Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
CA2491466A1 (en)	2002-07-09	2004-01-15	Sharlene Adams	Methods and compositions relating to isoleucine boroproline compounds
AU2003291403A1 (en)	2002-11-08	2004-06-03	Neurogen Corporation	3-substituted-6-aryl pyridined as ligands of c5a receptors
EP1567464B1 (en)	2002-12-02	2007-04-18	Solvias AG	Catalytic hydrogeneration of carbon-heteroatom double bonds
US7390806B2 (en)	2002-12-18	2008-06-24	Anacor Pharmaceuticals, Inc.	Antibiotics containing borinic acid complexes and methods of use
AU2003299821B2 (en)	2002-12-18	2010-02-18	Anacor Pharmaceuticals, Inc.	Antibiotics containing borinic acid complexes and methods of use
MXPA05009885A (es)	2003-03-14	2005-12-05	Astrazeneca Ab	Nuevas triazolonas fusionadas y los usos de las mismas.
WO2005000200A2 (en)	2003-05-09	2005-01-06	Sugen, Inc.	Novel kinases
EP1638578A4 (en)	2003-06-16	2009-04-01	Anacor Pharmaceuticals Inc	BORON-CONTAINING THERAPEUTIC AGENTS WITH HYDROLYTIC RESISTANCE AND METHODS OF USE THEREOF
JP2005022986A (ja) *	2003-06-30	2005-01-27	Sankyo Co Ltd	Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
AU2004253267B2 (en)	2003-07-03	2008-12-04	F. Hoffmann-La Roche Ag	Dual NK1/NK3 antagonists for treating schizophrenia
AU2004312510A1 (en)	2003-12-29	2005-07-21	3M Innovative Properties Company	Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
US10022424B2 (en)	2004-05-12	2018-07-17	The Brigham And Women's Hospital, Inc.	Use of gelsolin to treat infections
AR049915A1 (es)	2004-06-14	2006-09-13	Anacor Pharmaceuticals Inc	Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko)	2004-06-22	2006-09-19	한국화학연구원	알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
WO2006062731A1 (en)	2004-11-19	2006-06-15	University Of North Texas Health Science Center At Fort Worth	Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en)	2005-01-31	2005-03-09	Univ Cambridge Tech	Compounds for use in chemical detection and/or quantitation
EP1853251B1 (en)	2005-02-16	2013-04-24	Anacor Pharmaceuticals, Inc.	Halogen-substituted boronophthalides for the treatment of infections
US7919422B2 (en)	2005-03-08	2011-04-05	Agency For Science, Technology And Research	Chiral bisoxazoline catalysts
US20060251689A1 (en)	2005-03-30	2006-11-09	Astion Development A/S	Treatment or prevention of pruritus
US20080234229A1 (en)	2005-08-18	2008-09-25	Auspex Pharmaceuticals, Inc.	Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
RU2008131324A (ru)	2005-12-30	2010-02-10	Анакор Фармасьютикалз, Инк. (Us)	Борсодержащие малые молекулы
SI2719388T1 (sl)	2006-02-16	2019-06-28	Anacor Pharmaceuticals, Inc.	Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem
EP2044091A4 (en)	2006-06-12	2010-08-04	Anacor Pharmaceuticals Inc	COMPOUNDS FOR TREATING A PERIODONTAL DISEASE
US20070286822A1 (en)	2006-06-12	2007-12-13	Anacor Pharmaceuticals Inc.	Compounds for the Treatment of Periodontal Disease
KR100848491B1 (ko)	2007-01-16	2008-07-28	영진약품공업주식회사	베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar)	2007-06-20	2019-10-20	Anacor Pharmaceuticals Inc	جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko)	2007-07-20	2009-05-07	한국전자통신연구원	생체신호 측정의복과 생체신호 처리시스템
US8039450B2 (en)	2008-03-06	2011-10-18	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-inflammatory agents
EP2187893A4 (en)	2008-03-06	2012-02-22	Anacor Pharmaceuticals Inc	SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
US20100256092A1 (en)	2008-05-12	2010-10-07	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
US8461336B2 (en)	2008-09-04	2013-06-11	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
WO2010045505A1 (en)	2008-10-15	2010-04-22	Anacor Pharmaceuticals, Inc	Boron-containing small molecules as anti-protozoal agents
WO2010045503A1 (en)	2008-10-15	2010-04-22	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-protozoal agents
AR088668A1 (es) *	2011-11-21	2014-06-25	Lilly Co Eli	Moleculas pequeñas que contienen boro
AR088669A1 (es) *	2011-11-21	2014-06-25	Lilly Co Eli	Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos

2006
- 2006-02-16 EP EP06735282.3A patent/EP1853251B1/en active Active
- 2006-02-16 MX MX2015007465A patent/MX369262B/es unknown
- 2006-02-16 PL PL06735282T patent/PL1853251T3/pl unknown
- 2006-02-16 NZ NZ560448A patent/NZ560448A/en unknown
- 2006-02-16 RU RU2007134429/04A patent/RU2414906C2/ru active
- 2006-02-16 WO PCT/US2006/005542 patent/WO2006089067A2/en active Application Filing
- 2006-02-16 PT PT181873902T patent/PT3424932T/pt unknown
- 2006-02-16 DK DK18187390.2T patent/DK3424932T3/da active
- 2006-02-16 EP EP18187390.2A patent/EP3424932B1/en active Active
- 2006-02-16 HU HUE15171026A patent/HUE040060T2/hu unknown
- 2006-02-16 HU HUE11154575A patent/HUE026021T2/en unknown
- 2006-02-16 ES ES18187390T patent/ES2872962T3/es active Active
- 2006-02-16 DK DK15171026.6T patent/DK2987796T3/en active
- 2006-02-16 CN CNA2006800119809A patent/CN101160124A/zh active Pending
- 2006-02-16 SI SI200632291T patent/SI2987796T1/sl unknown
- 2006-02-16 ES ES11154575.2T patent/ES2540966T3/es active Active
- 2006-02-16 DK DK11154575.2T patent/DK2343304T3/en active
- 2006-02-16 EP EP15171026.6A patent/EP2987796B1/en active Active
- 2006-02-16 PL PL15171026T patent/PL2987796T3/pl unknown
- 2006-02-16 CN CN201010231477.2A patent/CN101914109B/zh active Active
- 2006-02-16 BR BRPI0608431A patent/BRPI0608431B8/pt active IP Right Grant
- 2006-02-16 US US11/357,687 patent/US7582621B2/en active Active
- 2006-02-16 PT PT111545752T patent/PT2343304E/pt unknown
- 2006-02-16 JP JP2007555382A patent/JP5038912B2/ja active Active
- 2006-02-16 KR KR1020077021229A patent/KR101337045B1/ko active IP Right Grant
- 2006-02-16 HU HUE18187390A patent/HUE054365T2/hu unknown
- 2006-02-16 PL PL18187390T patent/PL3424932T3/pl unknown
- 2006-02-16 PT PT67352823T patent/PT1853251E/pt unknown
- 2006-02-16 KR KR1020137021530A patent/KR101456815B1/ko active IP Right Grant
- 2006-02-16 NZ NZ578297A patent/NZ578297A/en unknown
- 2006-02-16 ES ES15171026.6T patent/ES2686981T3/es active Active
- 2006-02-16 ES ES06735282T patent/ES2414095T3/es active Active
- 2006-02-16 EP EP11154575.2A patent/EP2343304B1/en active Active
- 2006-02-16 KR KR1020137021906A patent/KR101426220B1/ko active IP Right Grant
- 2006-02-16 ZA ZA200707408A patent/ZA200707408B/xx unknown
- 2006-02-16 SI SI200632404T patent/SI3424932T1/sl unknown
- 2006-02-16 SI SI200631937T patent/SI2343304T1/sl unknown
- 2006-02-16 KR KR1020107017187A patent/KR101337068B1/ko active IP Right Grant
- 2006-02-16 CA CA2597982A patent/CA2597982C/en active Active
- 2006-02-16 PL PL11154575T patent/PL2343304T3/pl unknown
- 2006-02-16 AU AU2006214247A patent/AU2006214247C1/en active Active
- 2006-02-16 NZ NZ598441A patent/NZ598441A/xx unknown
- 2006-02-16 PT PT15171026T patent/PT2987796T/pt unknown
2007
- 2007-08-06 IL IL185080A patent/IL185080A/en active IP Right Grant
2008
- 2008-03-11 HK HK08102801.7A patent/HK1109735A1/xx unknown
- 2008-03-11 HK HK12100416.2A patent/HK1160139A1/xx not_active IP Right Cessation
2009
- 2009-07-21 US US12/507,010 patent/US8039451B2/en active Active
- 2009-08-27 ZA ZA2009/05950A patent/ZA200905950B/en unknown
2010
- 2010-07-20 AU AU2010203096A patent/AU2010203096C1/en active Active
- 2010-07-22 IL IL207156A patent/IL207156A/en active Protection Beyond IP Right Term
- 2010-07-28 ZA ZA2010/05380A patent/ZA201005380B/en unknown
- 2010-08-05 JP JP2010175989A patent/JP6046876B2/ja active Active
- 2010-08-10 RU RU2010133524A patent/RU2606947C2/ru active
2011
- 2011-03-01 AU AU2011200994A patent/AU2011200994A1/en not_active Abandoned
- 2011-09-01 US US13/224,252 patent/US8440642B2/en active Active
2012
- 2012-09-20 JP JP2012207001A patent/JP2013018778A/ja active Pending
2013
- 2013-04-30 US US13/874,329 patent/US8889656B2/en active Active
2014
- 2014-01-27 US US14/165,428 patent/US20140142064A1/en not_active Abandoned
- 2014-04-09 JP JP2014080464A patent/JP2014132031A/ja active Pending
- 2014-11-10 US US14/537,694 patent/US20150065459A1/en not_active Abandoned
2015
- 2015-09-17 ZA ZA2015/06944A patent/ZA201506944B/en unknown
- 2015-09-24 JP JP2015187408A patent/JP2016020374A/ja active Pending
- 2015-12-21 US US14/977,052 patent/US20160108063A1/en not_active Abandoned
2016
- 2016-08-23 HK HK16110032.1A patent/HK1221956A1/zh unknown
- 2016-11-18 US US15/355,813 patent/US20170066788A1/en not_active Abandoned
- 2016-11-23 RU RU2016145916A patent/RU2016145916A/ru not_active Application Discontinuation
2017
- 2017-02-15 JP JP2017025789A patent/JP2017105826A/ja active Pending
2018
- 2018-09-18 CY CY181100962T patent/CY1120695T1/el unknown
- 2018-10-18 US US16/164,331 patent/US20190048026A1/en not_active Abandoned
2019
- 2019-07-12 US US16/510,135 patent/US20190330245A1/en not_active Abandoned
2020
- 2020-06-08 LU LU00157C patent/LUC00157I2/fr unknown
- 2020-06-23 FR FR20C1024C patent/FR20C1024I2/fr active Active
- 2020-06-24 NL NL301049C patent/NL301049I2/nl unknown
- 2020-06-25 HU HUS2000019C patent/HUS2000019I1/hu unknown
- 2020-07-30 CY CY2020027C patent/CY2020027I1/el unknown
- 2020-08-14 LT LTPA2020524C patent/LTC2343304I2/lt unknown
- 2020-11-16 US US17/098,636 patent/US20210070780A1/en not_active Abandoned
2021
- 2021-05-19 CY CY20211100432T patent/CY1124503T1/el unknown

Also Published As

Publication number	Publication date
DK3424932T3 (da)	2021-05-25
US20210070780A1 (en)	2021-03-11
PT3424932T (pt)	2021-05-19
EP2987796A1 (en)	2016-02-24
KR20070112390A (ko)	2007-11-23
CY1124503T1 (el)	2022-07-22
US20130244980A1 (en)	2013-09-19
JP2010248265A (ja)	2010-11-04
MX369262B (es)	2019-11-04
US7582621B2 (en)	2009-09-01
ES2414095T3 (es)	2013-07-18
CY2020027I2 (el)	2021-01-27
RU2010133524A (ru)	2012-02-20
DK2987796T3 (en)	2018-09-17
RU2007134429A (ru)	2009-03-27
JP2014132031A (ja)	2014-07-17
NZ560448A (en)	2009-08-28
RU2606947C2 (ru)	2017-01-10
US20100190748A1 (en)	2010-07-29
PL1853251T3 (pl)	2013-09-30
AU2011200994A1 (en)	2011-03-31
SI2343304T1 (sl)	2015-08-31
HUE026021T2 (en)	2016-05-30
EP2343304A1 (en)	2011-07-13
ES2540966T3 (es)	2015-07-15
HUS2000019I1 (hu)	2020-07-28
ZA201506944B (en)	2018-08-29
JP2013018778A (ja)	2013-01-31
IL185080A0 (en)	2008-08-07
EP1853251A2 (en)	2007-11-14
CN101160124A (zh)	2008-04-09
PL2343304T3 (pl)	2015-09-30
CY2020027I1 (el)	2021-01-27
NZ598441A (en)	2013-07-26
CA2597982C (en)	2014-07-08
US8889656B2 (en)	2014-11-18
HK1160139A1 (en)	2012-08-10
LUC00157I1 (nl)	2020-06-08
SI3424932T1 (sl)	2021-08-31
IL185080A (en)	2012-07-31
PL2987796T3 (pl)	2018-12-31
ZA200905950B (en)	2010-11-24
LTC2343304I2 (lt)	2022-11-10
NL301049I2 (nl)	2020-09-10
PT1853251E (pt)	2013-07-19
CA2597982A1 (en)	2006-08-24
ZA201005380B (en)	2016-08-31
US20190048026A1 (en)	2019-02-14
AU2006214247B2 (en)	2010-08-05
SI2987796T1 (sl)	2018-11-30
BRPI0608431B1 (pt)	2020-09-15
FR20C1024I2 (fr)	2021-07-09
WO2006089067A3 (en)	2007-07-19
US8440642B2 (en)	2013-05-14
PT2343304E (pt)	2015-08-26
EP1853251A4 (en)	2010-01-13
JP2017105826A (ja)	2017-06-15
BRPI0608431B8 (pt)	2021-05-25
RU2414906C2 (ru)	2011-03-27
HK1109735A1 (en)	2008-06-20
HUE054365T2 (hu)	2021-09-28
US20150065459A1 (en)	2015-03-05
KR101337068B1 (ko)	2013-12-06
AU2010203096C1 (en)	2012-09-20
EP3424932B1 (en)	2021-04-07
US20190330245A1 (en)	2019-10-31
ES2686981T3 (es)	2018-10-23
US8039451B2 (en)	2011-10-18
JP5038912B2 (ja)	2012-10-03
KR20130100019A (ko)	2013-09-06
IL207156A (en)	2014-04-30
NZ578297A (en)	2010-11-26
EP1853251B1 (en)	2013-04-24
CN101914109B (zh)	2014-07-23
US20060234981A1 (en)	2006-10-19
AU2006214247A1 (en)	2006-08-24
EP3424932A1 (en)	2019-01-09
KR20100105869A (ko)	2010-09-30
US20160108063A1 (en)	2016-04-21
AU2010203096B2 (en)	2010-12-02
LTPA2020524I1 (lt)	2020-09-10
KR101426220B1 (ko)	2014-08-05
JP2016020374A (ja)	2016-02-04
JP2008535781A (ja)	2008-09-04
CN101914109A (zh)	2010-12-15
EP2343304B1 (en)	2015-06-10
KR20130095330A (ko)	2013-08-27
ZA200707408B (en)	2009-11-25
AU2010203096A1 (en)	2010-08-12
PT2987796T (pt)	2018-10-18
JP6046876B2 (ja)	2016-12-21
US20170066788A1 (en)	2017-03-09
KR101337045B1 (ko)	2013-12-05
WO2006089067A2 (en)	2006-08-24
FR20C1024I1 (nl)	2020-07-31
RU2016145916A (ru)	2018-05-23
DK2343304T3 (en)	2015-06-29
BRPI0608431A2 (pt)	2009-12-29
HK1221956A1 (zh)	2017-06-16
AU2006214247C1 (en)	2012-11-08
PL3424932T3 (pl)	2021-09-20
US20110319361A1 (en)	2011-12-29
LUC00157I2 (nl)	2021-07-06
KR101456815B1 (ko)	2014-10-31
CY1120695T1 (el)	2019-12-11
HUE040060T2 (hu)	2019-02-28
ES2872962T3 (es)	2021-11-03
US20140142064A1 (en)	2014-05-22
RU2016145916A3 (nl)	2020-07-21
EP2987796B1 (en)	2018-08-08

Publication	Publication Date	Title
NL301150I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl)	2020-07-01	Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I1 (nl)	2020-06-17	Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301261I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301299I2 (nl)	2024-12-11	Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL300946I2 (nl)	2018-09-26	Brexpiprazole, desgewenst in de vorm van een zout
NL301021I1 (nl)	2019-12-18	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301067I2 (nl)	2020-10-28	Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301199I2 (nl)	2023-02-16	Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL300909I2 (nl)	2017-12-19	Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301106I1 (nl)	2021-06-02	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301057I2 (nl)	2020-09-10	Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL300971I2 (nl)	2019-04-11	Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300913I2 (nl)	2017-12-20	Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL301033I2 (nl)	2020-04-15	Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL300974I2 (nl)	2022-04-06	Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301209I2 (nl)	2023-01-24	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301037I2 (nl)	2020-05-12	Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301041I2 (nl)	2020-09-14	Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan
NL301202I1 (nl)	2022-11-09	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL300863I2 (nl)	2017-08-03	Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL301020I2 (nl)	2020-04-21	Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat